Navigation Links
Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences

PRINCETON, N.J., Sept. 5 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the 3rd Annual Citi Biotech Day being held September 8, 2008, at the Citi Executive Conference Center, New York, NY. Management will also present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008, at the Grand Hyatt Hotel, New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide a brief overview of the company followed by a question and answer session at both conferences.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.


Kurt Leutzinger

Chief Financial Officer

Office: +1 (609) 613-4110

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
3. Pharmasset Joins Russell 3000 Index
4. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
5. Pharmasset Selected to Join the NASDAQ Biotechnology Index
6. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
7. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
8. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
9. Pharmasset Receives $10 Million of Working Capital
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
Post Your Comments:
(Date:12/1/2015)... 1, 2015  Twist Bioscience, a company focused on synthetic ... Ph.D., has been selected as one of Foreign ... the building blocks of life . Each year, Foreign ... contributions and work have changed lives and are shaping the ... is an honor to be recognized among these incredible global ...
(Date:12/1/2015)... , Dec. 1, 2015  The Minnesota High ... of the 2015 Tekne Award in the Small and ... at the Minneapolis Convention Center, ... played a significant role in developing new technologies that ... around the world. Clostridium difficile infection ...
(Date:12/1/2015)... ... December 01, 2015 , ... Park Systems , world ... scanning ion conductance microscopy module to Park NX10 that is the only product ... SICM benefits virtually all materials characterization that require measurements in liquid such as ...
(Date:12/1/2015)... Dec. 1, 2015  Symic, a clinical-stage biotherapeutics company ... matrix (ECM), today announced that it has secured $25 ... company,s pipeline, including its lead candidates SB-030 and SB-061. ... the participation by all existing major investors, as well ... total capital raised by Symic to over $43 million ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):